By Dean Baker | CEPR | July 16, 2019 Austin Frakt had a peculiar piece in the NYT Upshot section, which told readers, “there is no single, best policy for drug prices.” The piece is peculiar because for some reason Frakt opts not to even consider the policy of direct public funding for research, which […]
Source